We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Sciex

SCIEX develops and sells scientific instrumentation, software, and services for the life science, clinical research, ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Serum Prostate-Specific Antigen Measured by Tandem Mass Spectrometry

By LabMedica International staff writers
Posted on 23 Oct 2014
Print article
AB Sciex\' API 5000 triple quadruple mass spectrometer
The API 5000 triple quadruple mass spectrometer (Photo courtesy of Sciex)
Prostate-specific antigen (PSA) is a widely used blood test for detection and monitoring of prostate disease and many clinicians assume that all test methods produce essentially the same results, though differences do exist.

PSA is a 34-kDa glycoprotein with chymotrypsin-like enzyme activity that circulates both in free forms and complexed to various enzyme inhibitors including anti-chymotrypsin and α2-macroglobulin. Prostate-specific antigen bound to α2-macroglobulin is not detected by commercial PSA immunoassays.

Scientists at the Mayo Clinic College of Medicine (Rochester, MN, USA) developed a strategy to use a mass spectrometry (MS) assay to measure PSA concentrations that measures only the immune-reactive forms. Prostate-specific antigen is immune extracted from serum using antibodies directed to different PSA epitopes. A combination of three monoclonal anti-PSA antisera, which are directed to different PSA epitopes, was used for immune extraction of PSA from serum. PSA was extracted from serum, trypsin digested, and the LSEPAELTDAVK peptide was quantitated.

Absolute quantitation was performed by liquid chromatography–tandem mass spectrometry using a CTC Analytics HTC PAL auto sampler (LEAP Technologies; Carrboro, NC, USA; www.leaptec.com), a Shimadzu 10-AD binary pumping system (Shimadzu Scientific Instruments; Columbia, MD, USA), and an API 5000 triple quadruple mass spectrometer (AB SCIEX; Framingham, MA, USA). Validation of clinical utility and comparisons with two immunoassays were performed using frozen sera aliquots from 100 men undergoing prostate biopsy, 50 negative, 50 with cancer, and five serial samples collected over time from five men with advanced prostate cancer.

The antibody extraction efficiency was greater than 99%. The assay has an analytic range from 1.2 to 76 ng/mL, with precision ranging from 8.6% at 1.5 ng/mL to 5.4% at 27 ng/mL. The mass spectrometry assay correlated well with the two commercial immunoassays. All three assays showed statistically equivalent separation of prostate cancer from benign disease using receiver operating characteristic curve analysis.

The authors concluded that their MS assays are the first potential reference mass spectrometry assays that measure the same forms of PSA as the commercial immunoassays. These assays can reliably quantitate PSA concentrations in male sera that closely match existing immunoassays, and these assays are traceable to the international PSA standard with the proteins and therefore make the measurement system incomplete. Another advantage of their immune extraction is the increase in the relative concentration of PSA caused when the peptides from the PSA in a larger sample of serum are re-suspended in a smaller injection volume of buffer for the MS. This increase in concentration helps improve the robustness of the MS assay. The study was published on the October 2014 issue of the journal Archives of Pathology & Laboratory Medicine.

Related Links:

Mayo Clinic College of Medicine
LEAP Technologies
AB SCIEX

New
Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
New
Automated Nucleic Acid Extraction System
NuActor
New
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus
New
Silver Supplier
Anti-Müllerian Hormone (AMH) ELISA Test
PCOCheck ELISA (CE)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: This image depicts a DNA molecule that is methylated on both strands on the center cytosine. DNA methylation plays an important role for epigenetic gene regulation in development and cancer (Photo courtesy of Wikimedia Commons)

Study Supports Use of Methylated DNA Biomarkers for Cancer Diagnosis and Prognosis

A recent study added weight to the theory that methylated DNA biomarkers could be used for cancer diagnosis and prognosis. Methylation is a biological process by which methyl groups are added to a DNA molecule.... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.